Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Postmenopausal Osteoporosis: later-stage trial registry
A small indexed set (15 trials) with no open enrollment listed right now.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · none currently recruiting · #1,140 of 28,707 conditions by registered trial count
Postmenopausal Osteoporosis: 15 US clinical trials tracked, none currently recruiting.
Postmenopausal Osteoporosis is the subject of 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 10 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Warner Chilcott, running 4 of these trials.
Enrollment posture brief
Registry condition postmenopausal-osteoporosis
OPEN 0 | RECR 0% | LATE 10 | EARLY 3 | RANK #1140 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Postmenopausal Osteoporosis has no open enrollment in this registry pull (15 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Postmenopausal Osteoporosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Postmenopausal Osteoporosis is recruiting below its size-band peers.
0 of 15 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Postmenopausal Osteoporosis research.
Warner Chilcott accounts for 4 of 15 trials (26.7%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Postmenopausal Osteoporosis enrolment sits around 379 participants.
Median target enrolment is 379 among the 15 trials that report a genuine target (sentinel values excluded). 3 of those (20%) plan for fewer than 100 participants.
-
Postmenopausal Osteoporosis research is mostly interventional.
14 interventional and 1 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
15 total, page 1 of 1
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
Angitia Biopharmaceuticals
NCT06577935
Dried Plums and Bone Health in Postmenopausal Women
Penn State University
NCT02822378
Anabolic Therapy in Postmenopausal Osteoporosis
Massachusetts General Hospital
NCT05010590
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
Hoffmann-La Roche
NCT02604836
A Study of Monthly Risedronate for Osteoporosis
Warner Chilcott
NCT00247273
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
Warner Chilcott
NCT00541658
PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
Hoffmann-La Roche
NCT02598453
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
Radius Health
NCT04064411
Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis
Gedeon Richter
NCT05087030
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
Amgen
NCT01796301
Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women
Warner Chilcott
NCT00918749
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
Novartis Pharmaceuticals
NCT00718861
Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate
Warner Chilcott
NCT00778154
Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Massachusetts General Hospital
NCT00086619
A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
Hoffmann-La Roche
NCT00303485
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 6 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Postmenopausal Osteoporosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Postmenopausal Osteoporosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Postmenopausal Osteoporosis page
15 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Postmenopausal Osteoporosis trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Warner Chilcott sponsors the most Postmenopausal Osteoporosis trials on record, review their full trial history before evaluating a specific study. See Warner Chilcott's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Postmenopausal Osteoporosis condition card totals 15 registered trials; most-linked intervention risedronate; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.